AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

This story originally appeared on Zacks

AstraZeneca’s AZN stock rose more than 5% on Monday after it presented some key cancer data at the European Society for Medical Oncology (ESMO) Congress over the weekend.

Detailed data from the head-to-head DESTINY-Breast03 phase III study showed that AstraZeneca and partner Daiichi Sankyo’s breast cancer drug, Enhertu reduced the risk of death or tumor progression by 72% in patients with HER2-positive metastatic breast cancer previously treated with Roche’s RHHBY Kadcyla (trastuzumab emtansine (T-DM1)) and a taxane. Kadcyla, also HER2-directed antibody drug conjugate (ADC) like Enhertu, is the current standard of treatment for previously treated HER2-positive metastatic breast cancer.

In the study, progression free survival (PFE – a key secondary endpoint), as assessed by investigators, in patients treated with Enhertu was 25.1 months, almost three times of 7.2 months for Kadcyla. In the previously treated HER2-positive metastatic breast cancer population, patients usually experience disease progression in less than a year when treated with current available HER2-directed treatments. Enhertu almost tripled PFS and provided a disease control rate exceeding 95% (compared to 77% for Kadcyla). AstraZeneca believes that this data on Enhertu is “groundbreaking” and shows that the drug has the potential to become the new standard of care for previously treated HER2-positive metastatic breast cancer.

Though the overall survival (OS – a key secondary endpoint) data are still immature and not statistically significant, the study indicated a strong trend toward improved OS compared to T-DM1.

The confirmed objective response rate (ORR) was 79.7% in the Enhertu arm versus 34.2% in the Kadcyla arm

Please note that Enhertu is already approved to treat unresectable or metastatic HER2-positive breast cancer in patients who have received two or more prior anti-HER2-based regimens in the metastatic setting based on data from the DESTINY-Breast01 study. AstraZeneca also presented updated data from DESTINY-Breast01 study at ESMO. The data showed an impressive median OS of 29.1 months in HER2-positive patients following two or more HER2-based regimens.

This year so far, AstraZeneca’s shares are up 17% compared with an increase of 8.5% for the industry.

Image Source: Zacks Investment Research

AstraZeneca had acquired joint development and commercialization rights to Enhertu from Japan’s Daiichi Sankyo in April 2019. Sales of Enhertu in the United States are recognized by Daiichi Sankyo while AstraZeneca records its share of profit from the sales of the drug in the United States as collaboration revenues. Enhertu was approved for its second indication, HER2+, metastatic gastric cancer in January 2021 while it is also being evaluated for other cancer types.

At ESMO, AstraZeneca also presented three-year data from the CASPIAN phase III study in its PD-L1 inhibitor, Imfinzi. The data showed that Imfinzi plus chemotherapy tripled patient survival at three years in first-line extensive-stage small cell lung cancer

Please note that Imfinzi is already approved for the first-line treatment of extensive-stage small cell lung cancer in combination with standard-of-care platinum chemotherapy in several countries based on OS data from the CASPIAN phase III study. The latest results from the CAPIAN study showed that Imfinzi plus chemotherapy resulted in a 29% reduction in the risk of death versus chemotherapy alone after a median follow up of more than three years. The data also showed that an estimated 17.6% of patients in the Imfinzi plus chemotherapy arm were alive at three years, versus 5.8% of those in the chemotherapy alone arm.  Median OS was 12.9 months in the Imfinzi plus chemotherapy arm against 10.5 for the chemotherapy alone arm.

Imfinzi is also approved to treat unresectable, stage III non-small-cell lung cancer (NSCLC).

Enhertu and Imfinzi are part of AstraZeneca’s flourishing oncology portfolio. Other key oncology drugs in AstraZeneca’s portfolio are Tagrisso and Lynparza. AstraZeneca markets Lynparza in partnership with MerckMRK.

AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

A better-ranked large biotech stock is Regeneron REGN, which has a Zacks Rank #1 (Strong Buy).

Regeneron’s shares have gained 32.7% this year so far. Its earnings estimates for 2021 and 2022 have risen from $50.00 per share to $58.89.

(We are reissuing this article to correct a mistake. The original article, issued on September 21, 2021, should no longer be relied upon.)  

Zacks’ Top Picks to Cash in on Artificial Intelligence

This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.

See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
 
AstraZeneca PLC (AZN): Free Stock Analysis Report
 
Roche Holding AG (RHHBY): Free Stock Analysis Report
 
Merck & Co., Inc. (MRK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research